market, Cushman predicts, more "people are going to just start trying [them]" whether there are data to back them up or not
T.BancroftC
National Law Review (Polsinelli PC) was explicit on April 22, 2026: removing a Category 2 bulk drug substance does not, on its own, authorize use of that substance in compounding or bring it within FDAs interim enforcement discretion policy for substances in Category 1. Even Category 1 substances are only under enforcement discretion, which is short of full authorization
doi:10.1016/j.cmet.2016.02.005 Bartels RD, Kelly KM, Rothman AJ
you need to know how much of the active compound is truly getting to where it needs to go
The interconversion between these two states is fundamental to cellular energy generation, enabling NAD+ to act as an electron carrier in glycolysis, the Krebs cycle, and oxidative phosphorylation